The biochips market size has grown rapidly in recent years. It will grow from $14.61 billion in 2025 to $16.97 billion in 2026 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to growth in genomics and proteomics research, expansion of pharmaceutical and biotech r&d programs, adoption of dna microarrays in genetic screening, increasing use of biochips in molecular diagnostics, development of microarray and microfluidic-based analytical platforms.
The biochips market size is expected to see rapid growth in the next few years. It will grow to $29.03 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rising demand for precision medicine and personalized therapies, growing utilization of lab-on-chip technologies in clinical testing, higher investment in biomarker discovery and translational research, expanding applications of biochips in agriculture and life sciences, increasing commercialization of advanced biochip-based diagnostic tools. Major trends in the forecast period include growing adoption of biochips in genetic sequencing and disease diagnostics, increasing use of protein and cell arrays for advanced biomolecular research, rising demand for lab-on-chip platforms in point-of-care testing, expansion of biochip applications in drug discovery and development, focus on miniaturization and high-throughput biological data analysis.
The biochips market is poised for growth due to the increasing adoption of personalized medicines. Personalized medicine involves tailoring medical treatments based on individual characteristics such as genetics or lifestyle, aiming to optimize effectiveness and minimize adverse effects. This trend is fueled by the potential of personalized medicine to offer more effective treatments, advancements in genomics, the rising complexity of diseases, and regulatory backing. Biochips play a crucial role in personalized medicine by enabling precise and individualized treatment plans based on a person's genetic profile. For instance, in February 2024, the FDA approved 16 novel personalized therapies for rare diseases in 2023, highlighting the momentum in personalized medicine adoption and its impact on the biochips market.
Leading companies in the biochips market are focusing on developing cutting-edge technologies such as organ-on-a-chip platforms to transform drug discovery and development processes. Organ-on-a-chip platforms are sophisticated microfluidic devices designed to mimic the physiological characteristics and functions of human organs on a smaller scale. For example, in April 2024, Boston Micro Fabrication (BMF) launched BMF Biotechnology Inc., specializing in biochips or organ-on-a-chip platforms for cultivating large-scale tissues in vitro. This advancement accelerates drug and cosmetic development by providing a testing and research platform outside the human body.
In June 2023, Randox Laboratories acquired Cellix Limited to bolster its expertise in benchtop flow cytometry, aligning with its commitment to personalized medicine and improved preventive healthcare. This acquisition expands Randox's portfolio and makes flow cytometry technology more accessible to a wider range of researchers and healthcare professionals. Cellix Limited, based in Ireland, specializes in creating biochips for various applications in the life sciences.
Major companies operating in the biochips market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Tecan Group Ltd., Cepheid Inc., Randox Laboratories Ltd., Takara Bio Inc., Luminex Corporation, Fluidigm Corporation, Micronit Microtechnologies B.V., Sphere Fluidics Limited, Sengenics, Arrayit Corporation, CustomArray Inc., NanoCellect Biomedical Inc., Dolomite Microfluidics, Biocartis NV.
North America was the largest region in the biochips market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biochips market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biochips market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are affecting the biochips market by increasing the cost of semiconductor substrates, microfluidic components, biosensor electronics, and assay reagents that rely on global manufacturing and cross-border supply chains, leading to higher production and procurement costs. The impact is more pronounced across dna chips, protein chips, and lab-on-chip platforms manufactured in Asia-Pacific and European hubs where imports of specialty materials and precision components are tariff sensitive. Biotechnology and pharmaceutical companies, academic and research institutes, and hospital diagnostic centers are experiencing extended purchasing cycles and pricing pressures due to tariff-driven cost pass-throughs. However, tariffs are also encouraging localized fabrication, regional component sourcing, and domestic biochip assembly initiatives that may strengthen supply resilience and stimulate long-term innovation investment.
The biochips market research report is one of a series of new reports that provides biochips market statistics, including biochips industry global market size, regional shares, competitors with a biochips market share, detailed biochips market segments, market trends and opportunities, and any further data you may need to thrive in the biochips industry. This biochips market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Biochips are compact devices containing an assortment of biological substances such as DNA, proteins, or cells, affixed onto a solid surface. They merge biological components with electronic systems for studying and manipulating biological data, finding extensive use in medical diagnostics, genetic sequencing, and other biotechnological domains.
The primary types of biochips include DNA chips (or DNA microarrays), protein chips, lab-on-chip systems, tissue arrays, and cell arrays. DNA chips allow the simultaneous analysis of numerous genes' expressions, leveraging technologies such as microarrays and microfluidics. These biochips find applications in drug discovery, agriculture, genomics, disease diagnostics, proteomics, and are utilized by diverse end users such as biotech firms, pharmaceutical companies, academic institutions, hospitals, and diagnostic centers.
The biochips market consists of sales of lab-on-a-chip (LOC) devices, cellular microarrays, and protein microarrays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The biochips market size is expected to see rapid growth in the next few years. It will grow to $29.03 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rising demand for precision medicine and personalized therapies, growing utilization of lab-on-chip technologies in clinical testing, higher investment in biomarker discovery and translational research, expanding applications of biochips in agriculture and life sciences, increasing commercialization of advanced biochip-based diagnostic tools. Major trends in the forecast period include growing adoption of biochips in genetic sequencing and disease diagnostics, increasing use of protein and cell arrays for advanced biomolecular research, rising demand for lab-on-chip platforms in point-of-care testing, expansion of biochip applications in drug discovery and development, focus on miniaturization and high-throughput biological data analysis.
The biochips market is poised for growth due to the increasing adoption of personalized medicines. Personalized medicine involves tailoring medical treatments based on individual characteristics such as genetics or lifestyle, aiming to optimize effectiveness and minimize adverse effects. This trend is fueled by the potential of personalized medicine to offer more effective treatments, advancements in genomics, the rising complexity of diseases, and regulatory backing. Biochips play a crucial role in personalized medicine by enabling precise and individualized treatment plans based on a person's genetic profile. For instance, in February 2024, the FDA approved 16 novel personalized therapies for rare diseases in 2023, highlighting the momentum in personalized medicine adoption and its impact on the biochips market.
Leading companies in the biochips market are focusing on developing cutting-edge technologies such as organ-on-a-chip platforms to transform drug discovery and development processes. Organ-on-a-chip platforms are sophisticated microfluidic devices designed to mimic the physiological characteristics and functions of human organs on a smaller scale. For example, in April 2024, Boston Micro Fabrication (BMF) launched BMF Biotechnology Inc., specializing in biochips or organ-on-a-chip platforms for cultivating large-scale tissues in vitro. This advancement accelerates drug and cosmetic development by providing a testing and research platform outside the human body.
In June 2023, Randox Laboratories acquired Cellix Limited to bolster its expertise in benchtop flow cytometry, aligning with its commitment to personalized medicine and improved preventive healthcare. This acquisition expands Randox's portfolio and makes flow cytometry technology more accessible to a wider range of researchers and healthcare professionals. Cellix Limited, based in Ireland, specializes in creating biochips for various applications in the life sciences.
Major companies operating in the biochips market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Tecan Group Ltd., Cepheid Inc., Randox Laboratories Ltd., Takara Bio Inc., Luminex Corporation, Fluidigm Corporation, Micronit Microtechnologies B.V., Sphere Fluidics Limited, Sengenics, Arrayit Corporation, CustomArray Inc., NanoCellect Biomedical Inc., Dolomite Microfluidics, Biocartis NV.
North America was the largest region in the biochips market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biochips market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biochips market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are affecting the biochips market by increasing the cost of semiconductor substrates, microfluidic components, biosensor electronics, and assay reagents that rely on global manufacturing and cross-border supply chains, leading to higher production and procurement costs. The impact is more pronounced across dna chips, protein chips, and lab-on-chip platforms manufactured in Asia-Pacific and European hubs where imports of specialty materials and precision components are tariff sensitive. Biotechnology and pharmaceutical companies, academic and research institutes, and hospital diagnostic centers are experiencing extended purchasing cycles and pricing pressures due to tariff-driven cost pass-throughs. However, tariffs are also encouraging localized fabrication, regional component sourcing, and domestic biochip assembly initiatives that may strengthen supply resilience and stimulate long-term innovation investment.
The biochips market research report is one of a series of new reports that provides biochips market statistics, including biochips industry global market size, regional shares, competitors with a biochips market share, detailed biochips market segments, market trends and opportunities, and any further data you may need to thrive in the biochips industry. This biochips market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Biochips are compact devices containing an assortment of biological substances such as DNA, proteins, or cells, affixed onto a solid surface. They merge biological components with electronic systems for studying and manipulating biological data, finding extensive use in medical diagnostics, genetic sequencing, and other biotechnological domains.
The primary types of biochips include DNA chips (or DNA microarrays), protein chips, lab-on-chip systems, tissue arrays, and cell arrays. DNA chips allow the simultaneous analysis of numerous genes' expressions, leveraging technologies such as microarrays and microfluidics. These biochips find applications in drug discovery, agriculture, genomics, disease diagnostics, proteomics, and are utilized by diverse end users such as biotech firms, pharmaceutical companies, academic institutions, hospitals, and diagnostic centers.
The biochips market consists of sales of lab-on-a-chip (LOC) devices, cellular microarrays, and protein microarrays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Biochips Market Characteristics
3. Biochips Market Supply Chain Analysis
4. Global Biochips Market Trends and Strategies
5. Biochips Market Analysis of End Use Industries
7. Global Biochips Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Biochips Total Addressable Market (TAM) Analysis for the Market
9. Biochips Market Segmentation
10. Biochips Market Regional and Country Analysis
11. Asia-Pacific Biochips Market
12. China Biochips Market
13. India Biochips Market
14. Japan Biochips Market
15. Australia Biochips Market
16. Indonesia Biochips Market
17. South Korea Biochips Market
18. Taiwan Biochips Market
19. South East Asia Biochips Market
20. Western Europe Biochips Market
21. UK Biochips Market
22. Germany Biochips Market
23. France Biochips Market
24. Italy Biochips Market
25. Spain Biochips Market
26. Eastern Europe Biochips Market
27. Russia Biochips Market
28. North America Biochips Market
29. USA Biochips Market
30. Canada Biochips Market
31. South America Biochips Market
32. Brazil Biochips Market
33. Middle East Biochips Market
34. Africa Biochips Market
36. Biochips Market Competitive Landscape and Company Profiles
37. Biochips Market Other Major and Innovative Companies
40. Biochips Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Biochips Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses biochips market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for biochips? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biochips market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Deoxyribonucleic Acid (DNA) Chips; Protein Chips; Lab-On-Chip; Tissue Arrays; Cell Arrays2) By Technology: Microarrays; Microfluidics
3) By Application: Drug Discovery And Development; Agriculture; Genomics; Disease Diagnostics; Proteomics; Other Applications
4) By End-User: Biotechnology And Pharmaceutical Companies; Academic And Research Institutes; Hospitals And Diagnostic Centers; Other End-Users
Subsegments:
1) By Deoxyribonucleic Acid (Dna) Chips: Gene Expression Chips; Snp (Single Nucleotide Polymorphism) Chips; Dna Microarrays2) By Protein Chips: Antibody Arrays; Protein Microarrays; Peptide Arrays
3) By Lab-On-Chip: Microfluidic Devices; Biosensors
4) By Tissue Arrays: Tumor Tissue Arrays; Normal Tissue Arrays
5) By Cell Arrays: Cell-Based Biochips; Cell Signaling Arrays
Companies Mentioned: Thermo Fisher Scientific Inc.; Roche Diagnostics International Ltd; Agilent Technologies Inc.; PerkinElmer Inc.; Illumina Inc.; Bio-Rad Laboratories Inc.; QIAGEN N.V.; Tecan Group Ltd.; Cepheid Inc.; Randox Laboratories Ltd.; Takara Bio Inc.; Luminex Corporation; Fluidigm Corporation; Micronit Microtechnologies B.V.; Sphere Fluidics Limited; Sengenics; Arrayit Corporation; CustomArray Inc.; NanoCellect Biomedical Inc.; Dolomite Microfluidics; Biocartis NV
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Biochips market report include:- Thermo Fisher Scientific Inc.
- Roche Diagnostics International Ltd
- Agilent Technologies Inc.
- PerkinElmer Inc.
- Illumina Inc.
- Bio-Rad Laboratories Inc.
- QIAGEN N.V.
- Tecan Group Ltd.
- Cepheid Inc.
- Randox Laboratories Ltd.
- Takara Bio Inc.
- Luminex Corporation
- Fluidigm Corporation
- Micronit Microtechnologies B.V.
- Sphere Fluidics Limited
- Sengenics
- Arrayit Corporation
- CustomArray Inc.
- NanoCellect Biomedical Inc.
- Dolomite Microfluidics
- Biocartis NV
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 16.97 Billion |
| Forecasted Market Value ( USD | $ 29.03 Billion |
| Compound Annual Growth Rate | 14.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
